Psychopharmacology of Obsessive-Compulsive Disorder

CNS Spectrums

Volumn 3, Issue S1, 1998, Pages 33-37

  Montgomery, Stuart A ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0012392791     PISSN: 10928529     EISSN: 21656509     Source Type: Journal    
DOI: 10.1017/S1092852900007203     Document Type: Article

References (38)

1. Montgomery, SA. Clomipramine in obsessional neurosis: a placebo controlled trial. Pharmaceut Med. 1980; 189–192.
2. Thoren, P, Asberg, M, Cronholm, B, Jornestedt, L, Traskman, L. Clomipramine treatment in obsessive compulsive disorder. I. A controlled clinical trial. Arch Gen Psychiatry. 1980; 37: 1281–1285.
3. Marks, IM, Stern, RS, Mawson, D, Cobb, J, McDonald, R. Clomipramine and exposure for obsessive compulsive rituals. Br J Psychiatry. 1980; 136: 1–25.
4. McDougle, CJ, Goodman, WK, Price, LH, et al. Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry. 1990; 147: 652–654.
5. Goodman, WK, Price, LH, Rasmussen, SA, Delgado, PL, Heninger, GR, Charney, DS. Efficacy of fluvoxamine in obsessive compulsive disorder. Arch Gen Psychiatry. 1989; 46: 36–44.
6. Perse, TL, Greist, JH, Jefferson, JW, Rosenfeld, JW, Dar, R. Fluvoxamine treatment of obsessive compulsive disorder. Am J Psychiatry. 1987; 144: 1543–1548.
7. Goodman, WK, Kozak, MJ, Liebowitz, M, White, KL. Treatment of obsessive-compulsive disorder with fluvoxamine:a multicentre, double-blind, placebo-controlled trial. Int Clin Psychopharmacol. 1996; 11: 21–30.
8. Montgomery, SA, Manceaux, A. Fluvoxamine in the treatment of obsessive compulsive disorder. Int Clin Psychopharmacol. 1992; 7(Suppl 1):5–9.
9. Montgomery, SA, McIntyre, A, Osterheider, M, et al, and The Lilly European OCD Study Group. A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive compulsive disorder. Eur Neuropsychopharmacol. 1993; 3: 143–152.
10. Tollefson, GD, Rampey, AH, Potvin, JH, et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry. 1994; 51: 559–567.
11. Greist, J, Chouinard, G, DuBoff, E, et al. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry. 1995; 52: 289–295.
12. Chouinard, G. Sertraline in the treatment of obsessive-compulsive disorder. Two double blind placebo-controlled studies. Int Clin Psychopharmacol. 1992; 7(Suppl. 2):37–41.
13. Zohar, J, Judge, R. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. Br J Psychiatry. 1996; 169: 468–474.
14. Flament, MF, Rapoport, JL, Berg, CJ. Clomipramine treatment of childhood OCD: a double-blind controlled study. Arch Gen Psychiatry. 1985; 42: 977–983.
15. Marks, IM, Lelliott, P, Basoglu, M, et al. Clomipramine, self exposure and therapist aided exposure for obsessive compulsive rituals. Br J Psychiatry. 1988; 152; 522–534.
16. Mavissakalian, M, Jones, B, Olson, S, Perel, J. Clomipramine in obsessive-compulsive disorder: clinical response and plasma levels. J Clin Psychopharmacol. 1990; 10: 261–268.
17. De Veaugh Geiss, J, Katz, RJ, Landau, P, et al. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry. 1991; 48: 730–738.
18. De Veaugh Geiss, J, Moroz, G, Biederman, J, et al. Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder: a multicentre trial. J Am Acad Child Adolesc Psychiatr. 1992; 31: 45–49.
19. Pigott, TA, Pato, M, Bernstein, SE, et al. Controlled comparison of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry. 1990; 47: 926–932.
20. Freeman, CP, Trimble, MR, Deakin, JFW, et al. Fluvoxamine or clomipramine in the treatment of obsessive-compulsive disorder? A multicenter, randomized double-blind, parallel group comparison. J Clin Psychiat. 1994; 55, 301–305.
21. Koran, LM, McElroy, SL, Davidson, JRT, Rasmussen, SA, Hollander, E, Jenike, MA. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison. J Clin Psychiat. 1996; 16: 121–129.
22. Milanfranchi, A, Ravagli, S, Lensi, P, Marazziti, D, Cassano, GB. A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol. 1997; 12: 131–136.
23. Smeraldi, E, Erzegovesi, S, Bianchi, I, et al. Fluvoxamine v. clomipramine treatment in obsessive-compulsive disorder: a preliminary study. New Trends Exp Clin Psych. 1992; 8: 63–65.
24. Bisserbe, JC, Lane, RM, Flament, MF. A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder. Eur Psychiat. 1997; 12: 82–93.
25. Greist, JH, Jefferson, JW, Kozak, KA, et al. A one year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol. 1995; 10: 57–65.
26. Hiss, H, Foa, E, Kozak, MJ. Relapse prevention program in the treatment of obsessive-compulsive disorder. J Consult Clin Psychol. 1994; 62: 801–808.
27. Leonard, HL, Swedo, SE, Rapoport, JL, Coffey, M, Cheslow, DL. Treatment of childhood obsessive compulsive disorder with clomipramine and desmethylimipramine: a double blind crossover comparison. Psychopharm Bull. 1988; 24: 93–95.
28. Riddle, MA, Scahill, L, King, RA, et al. Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatr. 1992; 31: 1062–1069.
29. Goodman, WK, Price, LH, Delgado, PL, et al. Specificity of serotonin reuptake inhibitors in the treatment of obsessive compulsive disorder: comparison of fluvoxamine and desipramine. Arch Gen Psychiatry. 1990; 47: 577–585.
30. Zohar, J, Insel, TR. Obsessive compulsive disorder: psychobiological approaches to diagnosis, treatment and pathophysiology. Biol Psychiatry. 1987; 22: 667–687.
31. Ananth, JV, Pecknold, JC, Van den Steen, N, Engelsmann, F. Double-blind comparative study of clomipramine and amitriptyline in obsessive neurosis. Prog Neuropsychopharm Biol Psychiat. 1981; 5: 257–262.
32. Montgomery, SA, Fineberg, NA, Montgomery, DB, Bullock, T. L-Tryptophan in obsessive compulsive disorder—a placebo controlled study. Eur Neuropsychopharmacol. 1992; 2(Suppl. 2):384.
33. Insel, TR, Murphy, DL, Cohen, RM, Alterman, I, Kilts, C, Linnoila, M. Obsessive compulsive disorder—a double blind trial of clomipramine and clorgyline. Arch Gen Psychiatry. 1983; 40: 605–612.
34. Vallejo, J, Olivares, J, Marcos, T, Bulbena, A, Menchon, JM. Clomipramine versus phenelzine in obsessive compulsive disorder. A controlled clinical trial. Br J Psychiatry. 1992; 161: 665–670.
35. Hewlett, WA, Vinogradov, S, Agras, WS. Clomipramine, clonazepam, and clonidine treatment of obsessive compulsive disorder. J Clin Psychopharmacol. 1992; 12: 420–430.
36. Ravizza, L, Barzega, G, Bellino, S, et al. Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder. Psychopharm Bull. 1996; 32: 677–682.
37. Grady, TA, Pigott, TA, L'Heureux, F, Hill, JL, Bernstein, SE, Murphy, DL. Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive compulsive disorder. Am J Psychiatry. 1993; 150: 819–821.
38. Lindsay, M, Craig, R, Andrews, G. Controlled trial of exposure and response prevention in obsessive-compulsive disorder. Br J Psychiat. 1997; 171: 135–139.